A practical guide to vaccinating the inflammatory bowel disease patient

American Journal of Gastroenterology

Volumn 105, Issue 6, 2010, Pages 1231-1238

  Wasan, Sharmeel K ^a   Baker, Stacey E ^a   Skolnik, Paul R ^a   Farraye, Francis A ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BCG VACCINE; CERTOLIZUMAB PEGOL; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLIXIMAB; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; MERCAPTOPURINE; NATALIZUMAB; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; RABIES VACCINE; ROTAVIRUS VACCINE; TETANUS TOXOID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TYPHOID VACCINE; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE;

ANKYLOSING SPONDYLITIS; ATAXIA; BLOOD PLACENTA BARRIER; CROHN DISEASE; DRUG CONTRAINDICATION; ENCEPHALITIS; ENTERITIS; ERYTHEMA; ERYTHEMA MULTIFORME; FEVER; HEPATITIS B VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFLUENZA VACCINATION; INJECTION SITE REACTION; JAPANESE ENCEPHALITIS VIRUS; MALAISE; MYALGIA; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TETANUS PROPHYLAXIS; TRAVEL; ULCERATIVE COLITIS; VACCINATION; VIRUS STRAIN; YELLOW FEVER FLAVIVIRUS;

ADULT; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INFANT, NEWBORN; INFLAMMATORY BOWEL DISEASES; TRAVEL MEDICINE; VACCINATION; VACCINES;

EID: 77953233079     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.733     Document Type: Review

References (54)

1. Keene JK, Lowe DK, Grosfeld JL et al. Disseminated varicella complicating ulcerative colitis. JAMA 1978; 239: 45-46
2. Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008; 159: 1217-1228
3. Melmed GY, Ippoliti AF, Papadakis KA et al. Patients with infl ammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006; 101: 1834-1840
4. Loras C, Saro C, Gonzalez-Huix F et al. Prevalence and factors related to hepatitis B and C in infl ammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009; 104: 57-63.
5. Centers for Disease Control and Prevention. Recommended Adult Immunization Schedule\United States 2009. MMWR Recomm Rep. 2008; 57. 53.
6. Dotan I, Vigodman S, Malter L et al. Azathioprine/6-mercaptopurine therapy has no signifi cant eff ect on cellular or humoral immune responses in patients with infl ammatory bowel disease. Gastroenterology 2007; 132: A-51.
7. Mamula P, Markowitz JE, Piccoli DA et al. Immune response to infl uenza vaccine in pediatric patients with infl ammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 851-856
8. Lu Y, Jacobson DL, Ashworth LA et al. Immune response to infl uenza vaccine in children with infl ammatory bowel disease. Am J Gastroenterol 2009; 104: 444-453
9. Gelinck LB, van der Bijl AE, Beyer WE et al. The eff ect of anti-tumour necrosis factor alpha treatment on the antibody response to infl uenza vaccination. Ann Rheum Dis 2008; 67: 713-716
10. Melmed GY, Frenck R, Barolet-Garcia C et al. TNF blockers and immunomodulators impair antibody responses to pneumococcal polysaccharide vaccine (PPV) in patients with infl ammatory bowel disease (IBD). Gastroenterology 2008; 134: A68.
11. Kwon OS, Park YS, Choi JH et al. A case of ulcerative colitis relapsed by infl uenza vaccination. Korean J Gastroenterol 2007; 49: 327-330
12. Fields SW, Baiocco PJ, Korelitz BI. Infl uenza vaccinations: should they really be encouraged for IBD patients being treated with immunosuppressives? Infl amm Bowel Dis 2009; 15: 649-51; author reply 51-52
13. Sands BE, Cuff ari C, Katz J et al. Guidelines for immunizations in patients with infl ammatory bowel disease. Infl amm Bowel Dis 2004; 10: 677-692
14. Melmed GY. Vaccination strategies for patients with infl ammatory bowel disease on immunomodulators and biologics. Infl amm Bowel Dis 2009; 15: 1410-1416
15. Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Infl amm Bowel Dis 2009; 15: 1399-1409
16. Battafarano DF, Battafarano NJ, Larsen L et al. Antigen-specifi c antibody responses in lupus patients following immunization. Arthritis Rheum 1998; 41: 1828-1834
17. Kaine JL, Kivitz AJ, Birbara C et al. Immune responses following administration of infl uenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007; 34: 272-279
18. Miller AE, Morgante LA, Buchwald LY et al. A multicenter, randomized, double-blind, placebo-controlled trial of infl uenza immunization in multiple sclerosis. Neurology 1997; 48: 312-314
19. Confavreux C, Suissa S, Saddier P et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001; 344: 319-326
20. Chalmers A, Scheifele D, Patterson C et al. Immunization of patients with rheumatoid arthritis against infl uenza: a study of vaccine safety and immunogenicity. J Rheumatol 1994; 21: 1203-1206
21. Fomin I, Caspi D, Levy V et al. Vaccination against infl uenza in rheumatoid arthritis: the eff ect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006; 65: 191-194
22. Del Porto F, Lagana B, Biselli R et al. Infl uenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine 2006; 24: 3217-3223
23. Abu-Shakra M, Press J, Varsano N et al. Specifi c antibody response aft er infl uenza immunization in systemic lupus erythematosus. J Rheumatol 2002; 29: 2555-2557
24. Holvast A, Huckriede A, Wilschut J et al. Safety and effi cacy of infl uenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006; 65: 913-918
25. Elkayam O, Bashkin A, Mandelboim M et al. The eff ect of infl iximab and timing of vaccination on the humoral response to infl uenza vaccination in patients with rheumatoid arthritis and anklosing spondylitis. Semin Arthritis Rheum; e-pub ahead of print 24 February 2009.
26. Elkayam O, Caspi D, Reitblatt T et al. The eff ect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2004; 33: 283-288
27. Mease PJ, Ritchlin CT, Martin RW et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment wiThetanercept. J Rheumatol 2004; 31: 1356-1361
28. Donati M, Zuckerman M, Dhawan A et al. Response to varicella immunization in pediatric liver transplant recipients. Transplantation 2000; 70: 1401-1404
29. Giebink GS, Warkentin PI, Ramsay NK et al. Titers of antibody to pneumococci in allogeneic bone marrow transplant recipients before and aft er vaccination with pneumococcal vaccine. J Infect Dis 1986; 154: 590-596
30. Lu Y, Jacobson D, Bousvaros A. Immunizations in patients with infl ammatory bowel disease. Infl amm Bowel Dis 2009; 15: 1417-1423
31. Winter ME. Basic Clinical Pharmacokinetics, 4Thedn, Lippincott Williams & Wilkins: Philadelphia, 2004.
32. Singh A, Englund K. Q: Who should receive the shingles vaccine? Cleve Clin J Med 2009; 76: 45-48
33. Kotton CN. Nailing down the shingles in IBD. Infl amm Bowel Dis 2007; 13: 1178-1179
34. Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2008; 57: 1-30.
35. Watson JC, Hadler SC, Dykewicz CA et al. Measles, mumps, and rubella\vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998; 47: 1-57.
36. Levin MJ. Varicella vaccination of immunocompromised children. J Infect Dis 2008; 197: S200-6.
37. Marin M, G ü ris D, Chaves SS et al. Prevention of varicella recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007; 56: 1-40.
38. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with infl ammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 1483-1490
39. Nielsen HJ, Mortensen T, Holten-Andersen M et al. Increased levels of specifi c leukocyte-and platelet-derived substances during normal antitetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol 2001; 36: 265-269
40. Brogan MD, Shanahan F, Oliver M et al. Defective memory B cell formation in patients with infl ammatory bowel disease following tetanus toxoid booster immunization. J Clin Lab Immunol 1987; 24: 69-74.
41. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2009*. Ann Intern Med 2009; 150: 40-44
42. Kane S. Abnormal Pap smears in infl ammatory bowel disease. Infl amm Bowel Dis 2008; 14: 1158-1160
43. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with infl ammatory bowel disease. Am J Gastroenterol 2008; 103: 631-636
44. ClinicalTrials.gov identifi er: NCT00727636.
45. Fiore AE, Shay DK, Broder K et al. Prevention and control of infl uenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57: 1-60.
46. Esteve M, Saro C, Gonzalez-Huix F et al. Chronic hepatitis B reactivation following infl iximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-1365
47. Montiel PM, Solis JA, Chirinos JA et al. Hepatitis B virus reactivation during therapy wiThetanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008; 28: 718-720
48. Viget N, Vernier-Massouille G, Salmon-Ceron D et al. Opportunistic infections in patients with infl ammatory bowel disease: prevention and diagnosis. Gut 2008; 57: 549-558
49. Vida Perez L, Gomez Camacho F, Garcia Sanchez V et al. Adequate rate of response to hepatitis B virus vaccination in patients with infl ammatory bowel disease. Med Clin (Barc) 2009; 132: 331-335
50. Cardell K, Akerlind B, Sallberg M et al. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis 2008; 198: 299-304.
51. Mahadevan U, Terdiman J, Church J et al. Infl iximab levels in infants born to women with infl ammatory bowel disease. Gastroenterology 2007; 132: A-144.
52. Dubinsky M, Abraham B, Mahadevan U. Management of the pregnant IBD patient. Infl amm Bowel Dis 2008; 14: 1736-1750
53. Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0 through 18 years\United States 2009. MMWR 2008;57. 51-52
54. Angel JB, Walpita P, Lerch RA et al. Vaccine-associated measles pneumonitis in an adult with AIDS. Ann Intern Med 1998; 129: 104-106